Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR)
Author(s) -
Berkay Ekici,
Mehmet Yaman,
Murathan Kucuk,
Seçkin Dereli,
Mustafa Yenerçağ,
Zerrin Yiğit,
Mehmet Memduh Baş,
Yusuf Karavelioğlu,
Hüseyin Altuğ Çakmak,
Tarık Kıvrak,
Hakan Özkan,
Cihan Altın,
Cengiz Şabanoğlu,
Burcu Demirkan,
Ali Ataş,
Fethi Kılıçaslan,
Hakan Altay,
İstemihan Tengiz,
Aycan Fahri Erkan,
Barış Kiliçaslan,
Fatih Erkam Olgun,
Murtaza Emre Durakoğlugil,
Aslıhan Alhan,
Mehdi Zoghi
Publication year - 2021
Publication title -
turk kardiyoloji dernegi arsivi-archives of the turkish society of cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.2
H-Index - 24
ISSN - 1016-5169
DOI - 10.5543/tkda.2021.63099
Subject(s) - ejection fraction , sacubitril , heart failure , medicine , valsartan , cardiology , ventricle , diuretic , natriuretic peptide , ace inhibitor , angiotensin converting enzyme , blood pressure
Heart failure (HF) is a growing public health problem with high morbidity and mortality. Recently, angiotensin receptor neprilysin inhibitor (ARNi) has emerged as a promising treatment for HF with reduced ejection fraction (HFrEF). Here, we shared our experience with the use of ARNi in HFrEF from multiple centers in Turkey.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom